StockData
Alumis Inc. logo

Alumis Inc. (ALMS) company profile

ALMSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 6/30
$4.84−0.30 (-5.84%)

Close on Nov 17, 2026Market cap $626.47MP/E –Yield –

About Alumis

Pharmaceutical Preparations, SIC 2834

Alumis Inc. is a clinical-stage biopharmaceutical company focused on developing targeted oral therapies to replace broad immunosuppression for patients with immune-mediated conditions. The company's lead product candidate is envudeucitinib, an allosteric Tyrosine Kinase 2 (TYK2) inhibitor being evaluated for plaque psoriasis and systemic lupus erythematosus. Its pipeline also includes A-005, a central nervous system-penetrant TYK2 inhibitor aimed at neuroinflammatory and neurodegenerative disorders, alongside lonigutamab, a monoclonal antibody targeting IGF-1R for thyroid eye disease acquired via its merger with ACELYRIN.

The company operates without internal manufacturing facilities, outsourcing clinical-stage production and supply of active pharmaceutical ingredients and raw materials to third-party contract manufacturers located internationally, including in India and Taiwan. Its clinical trials and patent protections span across the United States, Europe, the United Kingdom, Latin America, and Asia-Pacific countries. The provided text does not disclose the specific location of its corporate headquarters.

Summary of the business section of Alumis's latest annual report, written by StockData.

Company profile

Company

Legal name
Alumis Inc.
Founded
2021
Headquarters
South San Francisco, CA
Address
280 East Grand Avenue 94080
Phone
(650) 231-6625
Website
alumis.com
Employees
224, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
PricewaterhouseCoopers LLP, San Jose, California

Stock & identifiers

Ticker
ALMS
Exchange
Nasdaq
IPO date
Jun 28, 2024
Shares outstanding
129M, Aug 6, 2026
Public float
$183.20M, Jun 30, 2025
Filer category
<br>Emerging growth company
SEC CIK
1847367
CUSIP
022307102
ISIN
US0223071020
FIGI
BBG01J7X4PN2
Share class FIGI
BBG01J7X4PP0
EIN
00-0000000

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Martin BablerPresident, CEO and Chairman, Director109,454
Sanam PangaliChief Legal Officer9,415
Mark Christopher BradleyChief Development Officer67,936
John R. SchroerChief Financial Officer23,924
Roy C. HardimanChief Business & Strategy Ofcr213,511
David M. GoldsteinChief Scientific Officer247,572
Jorn DrappaChief Medical Officer56,299
Derrick RichardsonSVP, People and Culture42,800
Sara KleinChief Legal Officer33,796
Srinivas AkkarajuDirector6,966,072
Patrick MachadoDirector10,617
Lynn A. TetraultDirector3,553
Sapna SrivastavaDirector3,553
Zhengbin YaoDirector27,082
James B. TananbaumDirector1,123,337
David E. GoelDirector10,645,966
AyurMaya Capital Management Company, LPDirector15,139,707
Alan ColowickDirector18,404

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryOption awardsIncentive payTotalvs. prior year
Martin Babler
President, Chief Executive Officer, and Chairman of the Board
$680.83K$4.74M$524.24K$5.95M-44%
David M. Goldstein, Ph.D.
Chief Scientific Officer
$526.40K$1.19M$294.79K$2.01M-38%
Jörn Drappa, M.D., Ph.D.
Chief Medical Officer
$523.76K$1.16M$293.30K$1.98M–

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Jun 28, 2024
Offer price
$16.00
Securities offered
13,125,000
Gross proceeds
$210.00M
Exchange
Nasdaq
First trading day
Jun 28, 2024
First-day close
$13.30-16.9%
Lock-up ends (est.)
Dec 25, 2024

“The initial public offering price per share is $16.00.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 221 full-time and 3 part-time employees, consisting of clinical, scientific, development, regulatory, finance, legal and operational personnel. We also retain ”

Corporate history

Events identified from SEC filings

See a number that looks wrong?